AIP
VRTX icon

Almanack Investment Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Almanack Investment Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,747
Closed -$376K – 462
2020
Q3 		$376K Buy
1,747
+78
+5% +$21.5K 0.05% 266
2020
Q2 		$485K Buy
1,669
+12
+0.7% +$3.25K 0.09% 132
2020
Q1 		$394K Buy
+1,657
New +$380K 0.08% 148

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Almanack Investment Partners's VRTX Position: Q4 2020 in Review

Almanack Investment Partners sold out of Vertex Pharmaceuticals (VRTX) in Q4 2020, closing a stake of 1,747 shares — an estimated $376K sold.

Almanack Investment Partners first reported a position in VRTX in Q1 2020 and held it in 3 quarters. The position peaked at $485K in Q2 2020. 971 funds tracked by Wall St. Rank hold VRTX as of Q4 2020.

  • Almanack Investment Partners reported no remaining Vertex Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Almanack Investment Partners sold 1,747 Vertex Pharmaceuticals shares in Q4 2020, an estimated $376K.
  • Almanack Investment Partners first reported a position in Vertex Pharmaceuticals in Q1 2020 and held it in 3 quarters.
  • Almanack Investment Partners's Vertex Pharmaceuticals position peaked at $485K in Q2 2020.
  • 971 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2020.

Based on Almanack Investment Partners's 13F filing for Q4 2020, filed 3 Feb 2021.